Eton Pharmaceuticals profit margin ETON
Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.
- Net margin, 12 months
- n/m
- a quarter missing
- Peer median
- 10.9%
Eton Pharmaceuticals' net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | n/a | n/a |
| FY2024 | n/a | n/a | n/a |
| FY2023 | −3.0% | −3.8% | 66.6% |
| FY2022 | −42.4% | −38.9% | 67.4% |
| FY2021 | −9.0% | −6.8% | 87.2% |
| FY2020 | n/a | n/a | n/a |
| FY2019 | n/a | n/a | 52.8% |
| FY2018 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | n/a | n/a | n/a | |
| Q1 FY26 | n/a | n/a | n/a | |
| Q4 FY25 | n/a | n/a | n/a | |
| Q3 FY25 | n/a | n/a | n/a | |
| Q2 FY25 | n/a | n/a | n/a | |
| Q1 FY25 | n/a | n/a | n/a | |
| Q4 FY24 | n/a | n/a | n/a | |
| Q3 FY24 | −15.8% | −22.6 pts | −15.1% | |
| Q2 FY24 | −21.3% | −20.5 pts | −20.0% | |
| Q1 FY24 | 2.7% | +28.7 pts | 1.6% | |
| Q4 FY23 | −3.0% | +39.5 pts | −3.8% | |
| Q3 FY23 | 6.8% | +54.0 pts | 5.7% |
Against its peers
Companies in Drug Manufacturers - General nearest Eton Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| ETONEton Pharmaceuticals | n/m |
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| PAHCPhibro Animal Health | 6.6% |
| ANIPANI Pharmaceuticals | 11.1% |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| HRMYHarmony Biosciences | 18.9% |
| PBHPrestige Consumer Healthcare | 15.6% |
| ABUSArbutus Biopharma | 84.2% |
| COLLCollegium Pharmaceutical | 5.9% |
| Peer median | 10.9% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Eton Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.